 |
66 Diseases |  |
138 Trials |
|
138 Trials |  |
1390 News |  |
| «12...345678910111213...2122» |
- | triptorelin / Generic mfg.
Journal: Triptorelin stimulated luteinizing hormone concentrations for diagnosing central precocious puberty: study of diagnostic accuracy. (Pubmed Central) - Mar 24, 2022
Measuring LH concentrations 180 min after triptorelin injection with a cut-off value of ≥3.4 IU/L demonstrated a high diagnostic accuracy compared to the GnRH test. Thus, stimulation with triptorelin can be used as a reliable alternative for diagnosing CPP in girls with premature thelarche.
- || triptorelin / Generic mfg.
Clinical, Journal: Long-Term Outcomes with Pharmacological Ovarian Suppression during Chemotherapy in Premenopausal Early Breast Cancer Patients. (Pubmed Central) - Mar 23, 2022
Thus, stimulation with triptorelin can be used as a reliable alternative for diagnosing CPP in girls with premature thelarche. Final analysis of the PROMISE-GIM6 trial provides reassuring results on the safety of GnRHa use during chemotherapy as a strategy to preserve ovarian function in premenopausal patients with early breast cancer, including those with hormone receptor-positive disease.
- | New P4 trial: Addition of Gonadotropin Releasing Hormone Agonist to Luteal Phase Support (clinicaltrials.gov) - Mar 17, 2022
P4, N=75, Not yet recruiting, Sponsor: Alexandria University
- | Xtandi (enzalutamide capsule) / Pfizer, Astellas, Erleada (apalutamide) / J&J, Firmagon (degarelix) / Astellas, Ferring
Trial initiation date, Metastases: OMPCa-ENSURE: Enhanced Systemic Combined With Local Treatment for Primary and Metastatic Lesions in Oligo-metastatic Prostate Cancer (clinicaltrials.gov) - Mar 16, 2022
P2, N=160, Recruiting, Sponsor: Fudan University
Final analysis of the PROMISE-GIM6 trial provides reassuring results on the safety of GnRHa use during chemotherapy as a strategy to preserve ovarian function in premenopausal patients with early breast cancer, including those with hormone receptor-positive disease. Initiation date: Jan 2022 --> Apr 2022
- | leuprorelin depot / Generic mfg.
Journal: Treatment with gonadotropin-releasing hormone analogs (GnRHa) in childhood and adolescence (Pubmed Central) - Mar 11, 2022
These analogs have proven both their efficacy and their safety. The aim of this paper is to review and update about the use of GnRHa in children and adolescents.
- Jardiance (empagliflozin) / Eli Lilly, Boehringer Ingelheim
Precise Analysis of the State HTA Progress in Ukraine: Results of the 1st Year of Implementation and Impact (In-person & Virtual) - Mar 8, 2022 - Abstract #ISPOR2022ISPOR_1561;
3 medicines were recommended for listing on the NEML or nomenclature (empagliflozin, tiotropium bromide, triptorelin) and 8 medicines were recommended for MEA, others - not recommended. As a result of the work done in the context of state HTA by full procedure, the total of 14 conclusions with recommendations were developed, 8 medicines were recommended for MEA and 2 medicines (empagliflozin, tiotropium bromide) were listed in the NEML due to CMU Decree №1431 dated 31 December, 2021.
- | triptorelin / Generic mfg.
Journal: Single Dose Gonadotropin-Releasing Hormone Agonist Luteal Support in Fresh Embryo Transfer: Variation in Timing, Type, and Dosage. (Pubmed Central) - Mar 8, 2022
A higher dose of 0.2 mg subcutaneous Decapeptyl was administered 2 days before fresh ET concurrent with routine progestogen support...Nonetheless, the OHSS rate was slightly increased in the study group (4.5 vs. 3.5%) despite using a mild stimulation protocol. New regime of GnRH agonist luteal support in addition to the standard progestogen support was found to be beneficial in overall IVF outcome.
- | Firmagon (degarelix) / Astellas, Ferring
Enrollment change: Degarelix in the Treatment of Endometriosis Recurrence (clinicaltrials.gov) - Feb 28, 2022
P3, N=360, Completed, Sponsor: Centre for Endocrinology and Reproductive Medicine, Italy
New regime of GnRH agonist luteal support in addition to the standard progestogen support was found to be beneficial in overall IVF outcome. N=100 --> 360
- | triptorelin / Generic mfg.
Journal: Positive effect of combined exercise on adipokines levels and pubertal signs in overweight and obese girls with central precocious puberty. (Pubmed Central) - Feb 24, 2022
Combined exercise increased adiponectin and decreased resistin and the rate of puberty. However, after 4 weeks of detraining, these effects diminished but did not disappear.
- ||||||| Rekovelle (follitropin delta) / Ferring
Trial completion, Trial completion date: Follitropin Delta in Long GnRH Agonist and GnRH Antagonist Protocols (BEYOND) (clinicaltrials.gov) - Feb 23, 2022
P3, N=437, Completed, Sponsor: Ferring Pharmaceuticals
However, after 4 weeks of detraining, these effects diminished but did not disappear. Active, not recruiting --> Completed | Trial completion date: Sep 2022 --> Feb 2022
- | triptorelin / Generic mfg.
Observational data, Journal: The efficacy and safety of triptorelin-therapy following conservative surgery for deep infiltrating endometriosis: A multicenter, prospective, non-interventional study in China. (Pubmed Central) - Feb 22, 2022
P=N/A
Triptorelin was well tolerated without serious adverse events.Triptorelin after conservative surgery for DIE improved symptoms over 24 months of follow up. The recurrence rate of symptoms was low and triptorelin was generally well tolerated.Trial registration number: ClinicalTrials.gov, NCT01942369.
- | Trial completion date, Trial primary completion date: The Use of GnRH Agonist Trigger for Final Follicle Maturation in Women Undergoing Assisted Reproductive Technologies (clinicaltrials.gov) - Feb 21, 2022
P4, N=282, Recruiting, Sponsor: American University of Beirut Medical Center
The recurrence rate of symptoms was low and triptorelin was generally well tolerated.Trial registration number: ClinicalTrials.gov, NCT01942369. Trial completion date: Oct 2021 --> Oct 2022 | Trial primary completion date: Jul 2021 --> Jul 2022
- || Opdivo (nivolumab) / Ono Pharma, BMS
Clinical, P2 data, Journal, PD(L)-1 Biomarker, IO biomarker: Neoadjuvant chemotherapy and immunotherapy in Luminal B-like breast cancer: results of the phase II GIADA trial. (Pubmed Central) - Feb 19, 2022
P2
Luminal B-like BCs with a Basal molecular subtype and/or a state of immune activation may respond to sequential anthracyclines and anti-PD-1. Our data generate hypotheses that, if validated, could guide immunotherapy development in this context.
- | clomifene citrate / Generic mfg.
Trial primary completion date: Mild Stimulation Protocol Using Clomiphene Citrate for Women With PCOS Undergoing in Vitro Fertilization (clinicaltrials.gov) - Feb 18, 2022
P4, N=154, Recruiting, Sponsor: American University of Beirut Medical Center
Our data generate hypotheses that, if validated, could guide immunotherapy development in this context. Trial primary completion date: Jul 2021 --> Jul 2022
- | Cetrotide (cetrorelix) / EMD Serono
Journal: Magnetic solid-phase extraction of high molecular weight peptides using stearic acid-functionalized magnetic hydroxyapatite nanocomposite: determination of some hypothalamic agents in biological samples. (Pubmed Central) - Feb 17, 2022
Under optimum conditions, the proposed method (MSPE-HPLC-UV) represented favorable linearity with R ≥ 0.9987, suitable intra- and inter-day precisions (RSD ≤ 6.9% and RSD ≤ 8.1%, respectively, n = 3), and limits of detection and quantification in the range of 0.75-1.12 ng mL and 2.50-3.75 ng mL, respectively. Eventually, the proposed method was used for the extraction and quantification of target therapeutic peptides in plasma and urine samples, and satisfactory relative recoveries were achieved in the range of 90.6-110.3%.
- | Trial completion, Trial completion date, Trial primary completion date: Progestin Primed Double Stimulation Protocol Versus Flexible GnRH Antagonist Protocol in Poor Responders (clinicaltrials.gov) - Feb 17, 2022
P3, N=90, Completed, Sponsor: El Shatby University Hospital for Obstetrics and Gynecology
Eventually, the proposed method was used for the extraction and quantification of target therapeutic peptides in plasma and urine samples, and satisfactory relative recoveries were achieved in the range of 90.6-110.3%. Not yet recruiting --> Completed | Trial completion date: Dec 2021 --> Sep 2021 | Trial primary completion date: Sep 2021 --> Mar 2021
- | Firmagon (degarelix) / Astellas, Ferring, NN1213 / Novo Nordisk
Enrollment closed, Monotherapy: High-Dose Brachytherapy in Treating Patients With Prostate Cancer (clinicaltrials.gov) - Feb 16, 2022
P1/2, N=163, Active, not recruiting, Sponsor: Stanford University
Not yet recruiting --> Completed | Trial completion date: Dec 2021 --> Sep 2021 | Trial primary completion date: Sep 2021 --> Mar 2021 Suspended --> Active, not recruiting
- | Suprefact (buserelin acetate) / Sanofi, Erleada (apalutamide) / J&J, Firmagon (degarelix) / Astellas, Ferring
Enrollment open, Trial completion date: Two Studies for Patients With High Risk Prostate Cancer Testing Less Intense Treatment for Patients With a Low Gene Risk Score and Testing a More Intense Treatment for Patients With a High Gene Risk Score, The PREDICT-RT Trial (clinicaltrials.gov) - Feb 3, 2022
P3, N=2478, Recruiting, Sponsor: NRG Oncology
Suspended --> Active, not recruiting Suspended --> Recruiting | Trial completion date: Dec 2038 --> Dec 2033
- || Xtandi (enzalutamide capsule) / Pfizer, Astellas, Eligard (leuprolide acetate) / Tolmar, Sanofi, Recordati
Enrollment closed, HEOR, Real-world evidence, Real-world, Metastases: A Study Called AWARENESS Using Data From Men in Alberta to Observe Treatment Patterns for Metastatic Castration-sensitive Prostate Cancer (clinicaltrials.gov) - Feb 2, 2022
P=N/A, N=400, Active, not recruiting, Sponsor: Bayer
Suspended --> Recruiting | Trial completion date: Dec 2038 --> Dec 2033 Not yet recruiting --> Active, not recruiting
- || triptorelin / Generic mfg.
Clinical, Journal: Fertility of Women Treated during Childhood with Triptorelin (Depot Formulation) for Central Precocious Puberty: The PREFER Study. (Pubmed Central) - Feb 2, 2022
The results, based on a limited sample of patients, suggest that CPP treated with triptorelin does not negatively impact women's fertility in adulthood. These results need to be consolidated with a subsequent study performed when these women will have reached their mid-thirties.
- || letrozole / Generic mfg., cisplatin / Generic mfg., paclitaxel / Generic mfg.
Clinical, Journal: GnRHa as a treatment for letrozole-resistant recurrent adult granulosa cell tumors: A case report. (Pubmed Central) - Feb 1, 2022
These results need to be consolidated with a subsequent study performed when these women will have reached their mid-thirties. Hormone therapy may be an alternative to treat recurrent granulosa cell tumors, and gonadotropin-releasing hormone agonists may be a rescue treatment for aromatase inhibitor-resistant cases.
- || Visanne (dienogest) / Mochida, Bayer
Clinical, Journal: Dienogest vs GnRH agonists as postoperative therapy after laparoscopic eradication of deep infiltrating endometriosis with bowel and parametrial surgery: a randomized controlled trial. (Pubmed Central) - Jan 29, 2022
Dienogest has proven to be as effective as GnRH agonists in preventing recurrence of DIE and associated pelvic pain after surgery. Also, it is better tolerated by patients.
- | triptorelin / Generic mfg.
Journal: Adjunct Triptorelin in the Treatment of Obsessive-Compulsive Disorder in Clients Receiving Selective Serotonin Reuptake Inhibitors (SSRIs). (Pubmed Central) - Jan 28, 2022
The effectiveness of triptorelin in the treatment of symptoms in clients with OCD was confirmed in our study. However, due to the limited research addressing this domain, future studies are suggested to clarify this conclusion.
- | Xtandi (enzalutamide capsule) / Pfizer, Astellas, Erleada (apalutamide) / J&J, Firmagon (degarelix) / Astellas, Ferring
New P2 trial, Metastases: OMPCa-ENSURE: Enhanced Systemic Combined With Local Treatment for Primary and Metastatic Lesions in Oligo-metastatic Prostate Cancer (clinicaltrials.gov) - Jan 27, 2022
P2, N=160, Recruiting, Sponsor: Fudan University
- | triptorelin / Generic mfg.
Journal: Silk fibroin double-layer microneedles for the encapsulation and controlled release of triptorelin. (Pubmed Central) - Jan 27, 2022
A linear decreasing relationship was observed between the diffusion coefficient and increased β-sheet content. After administration to rats, SF-MNs exhibited long-term testosterone inhibition and maintained castration levels for ≥7 d. Manipulable mechanical properties and release behavior combined with biocompatibility and biodegradability render SF-MNs as viable long-term transdermal delivery devices for triptorelin.
- | Enrollment open: GUIDANCE: Two Studies for Patients With Unfavorable Intermediate Risk Prostate Cancer Testing Less Intense Treatment for Patients With a Low Gene Risk Score and Testing a More Intense Treatment for Patients With a Higher Gene Risk Score (clinicaltrials.gov) - Jan 24, 2022
P3, N=2050, Recruiting, Sponsor: NRG Oncology
After administration to rats, SF-MNs exhibited long-term testosterone inhibition and maintained castration levels for ≥7 d. Manipulable mechanical properties and release behavior combined with biocompatibility and biodegradability render SF-MNs as viable long-term transdermal delivery devices for triptorelin. Not yet recruiting --> Recruiting
- || Xtandi (enzalutamide capsule) / Pfizer, Astellas, Eligard (leuprolide acetate) / Tolmar, Sanofi, Recordati
Trial completion date, Trial primary completion date, HEOR, Real-world evidence, Real-world, Metastases: A Study Called AWARENESS Using Data From Men in Alberta to Observe Treatment Patterns for Metastatic Castration-sensitive Prostate Cancer (clinicaltrials.gov) - Jan 19, 2022
P=N/A, N=400, Not yet recruiting, Sponsor: Bayer
Not yet recruiting --> Recruiting Trial completion date: Jul 2022 --> Sep 2022 | Trial primary completion date: Jul 2022 --> Sep 2022
- |||| goserelin acetate / Generic mfg., leuprorelin depot / Generic mfg., triptorelin / Generic mfg.
GnRH agonist: eg, goserelin, triptorelin, leuprolide ✍️ Effectively lowers T to castrate levels by approximately ~28 days #PCaChat (Twitter) - Jan 12, 2022
- || New P2a trial, Metastases: First Strike, Second Strike Therapies for High Risk Metastatic Castration Sensitive Prostate Cancer (clinicaltrials.gov) - Jan 11, 2022
P2a, N=31, Recruiting, Sponsor: H. Lee Moffitt Cancer Center and Research Institute
- Nubeqa (darolutamide) / Bayer, Orion Corp
Long-term safety of darolutamide in patients with metastatic castration-resistant prostate cancer. (In-Person & On Demand | Level 1, West Hall - N5) - Jan 5, 2022 - Abstract #ASCOGU2022ASCO_GU_322;
P1, P2
Prior systemic anticancer treatments taken by more than 1 patient were bicalutamide (n = 10); cyproterone (n = 3); and triptorelin and leuprorelin (n = 2 each). Extended darolutamide treatment > 2 years in this small group of patients with mCRPC was generally well tolerated, with safety and tolerability consistent with that previously reported.
- triptorelin / Generic mfg.
Baseline parameters of patients with prostate cancer (PCa) initiating a triptorelin treatment for at least 12 months in real life, TALISMAN study interim analysis. (In-Person & On Demand | Level 1, West Hall) - Jan 5, 2022 - Abstract #ASCOGU2022ASCO_GU_293;
P=N/A
The ongoing TALISMAN study is collecting data on patients, PCa aggressiveness, supportive care, which may impact total duration of triptorelin treatment. Statistical analyses at completion of study will give additional results.
- | docetaxel / Generic mfg.
Enrollment closed, Trial completion date, Trial initiation date: Androgen Deprivation Therapy Combined With Docetaxel for High Risk Prostate Cancer (clinicaltrials.gov) - Jan 3, 2022
P2, N=75, Active, not recruiting, Sponsor: Hongqian Guo
Statistical analyses at completion of study will give additional results. Recruiting --> Active, not recruiting | Trial completion date: Sep 2023 --> Dec 2023 | Initiation date: Sep 2020 --> Dec 2018
- | triptorelin / Generic mfg.
Journal: Ideal Lag Time from Ovulation to Oocyte Aspiration Using a GnRH Agonist Trigger. (Pubmed Central) - Dec 25, 2021
Our study identified a positive correlation between lag time and both the number of M2 oocytes and the total number of oocytes aspirated-factors which lead to an increased rate of successful pregnancies. Further research is necessary.
- | triptorelin / Generic mfg.
Journal: Investigation of Specific Targeting of Triptorelin-Conjugated Dextran-Coated Magnetite Nanoparticles as a Targeted Probe in GnRH Cancer Cells in MRI. (Pubmed Central) - Dec 25, 2021
The relaxivity calculations for SPION@CMD@triptorelin showed a suitable r and r/r with values of 31.75 mM·s and 10.26, respectively. Our findings confirm that triptorelin-targeted SPIONs could provide a T-weighted probe contrast agent that has the great potential for the diagnosis of GnRH-positive cancer in MRI.
- Suprefact (buserelin acetate) / Sanofi, Firmagon (degarelix) / Astellas, Ferring
Cardiovascular adverse events-related to GnRH agonists and GnRH antagonists: Analysis of real-life data from Eudra-Vigilance database (Green Area, Room 5) - Dec 22, 2021 - Abstract #EAU2022EAU_1360;
Real-life data suggest GnRH agonists are associated with higher cardiovascular AEs when compared to GnRH antagonists. Clinicians should consider these data when prescribing HT especially in young patients.
- || triptorelin / Generic mfg.
Enrollment closed: TALISMAN: Treatment of Aggressive Prostate Cancer in Real Life: Initiation, Schedule and Management of Triptorelin Treatment. (clinicaltrials.gov) - Dec 17, 2021
P=N/A, N=817, Active, not recruiting, Sponsor: Ipsen
Clinicians should consider these data when prescribing HT especially in young patients. Recruiting --> Active, not recruiting
- | leuprorelin depot / Generic mfg., bicalutamide / Generic mfg.
Journal: Decreased testosterone recovery after androgen deprivation therapy for prostate cancer. (Pubmed Central) - Dec 16, 2021
Increasing age and duration of ADT therapy are associated with decreased likelihood to recover normal testosterone levels after cessation of therapy. The use of the ADT agent goserelin was also associated with decreased testosterone recovery for unclear reasons.
- || triptorelin / Generic mfg.
Clinical, Journal: Efficacy of Triptorelin 3-Month Depot Compared to 1-Month Depot for the Treatment of Korean Girls with Central Precocious Puberty in Single Tertiary Center. (Pubmed Central) - Dec 16, 2021
This study showed that the efficacy of long-acting triptorelin 3-month was comparable to 1-month depot regarding hormonal suppression and inhibition of bone maturation. The triptorelin 11.25 mg 3-month depot is an effective treatment for girls with CPP.
- | triptorelin / Generic mfg.
New trial: Hyperbaric Oxygen in (EUDRACT) - Dec 10, 2021
P=N/A, N=40, Not yet recruiting, Sponsor: Jos
- |||| goserelin acetate / Generic mfg., leuprorelin depot / Generic mfg., triptorelin / Generic mfg.
GnRH agonist: eg, goserelin, triptorelin, leuprolide Effectively lowers testosterone after ~3 days & castration levels achieved after ~28 days #PCaChat (Twitter) - Dec 9, 2021
- | Mifeprex (mifepristone) / Danco Laboratories
New P1 trial: LUOMITTOA: Long-term Use of Mifepristone in the Treatment of Adenomyosis (clinicaltrials.gov) - Dec 9, 2021
P1, N=140, Not yet recruiting, Sponsor: Women's Hospital School Of Medicine Zhejiang University
- |||||| Xtandi (enzalutamide capsule) / Pfizer, Astellas, Eligard (leuprolide acetate) / Tolmar, Sanofi, Recordati
New trial, HEOR, Real-world evidence, Real-world, Metastases: A Study Called AWARENESS Using Data From Men in Alberta to Observe Treatment Patterns for Metastatic Castration-sensitive Prostate Cancer (clinicaltrials.gov) - Dec 7, 2021
P=N/A, N=400, Not yet recruiting, Sponsor: Bayer
- Treatment trends among men with metastatic Castration Sensitive Prostate Cancer (mCSPC): Results from the European component of an international study () - Nov 30, 2021 - Abstract #EMUC2021EMUC_261;
This suggests unmet needs for novel therapies in mCRPC. Funding Pfizer
- || norethindrone / Generic mfg.
Review, Journal: Treatments for seizures in catamenial (menstrual-related) epilepsy. (Pubmed Central) - Nov 29, 2021
Our review highlights an overall deficiency in the literature base on the effectiveness of a wide range of other hormonal and non-hormonal interventions currently being used in practice, particularly for those women who do not have regular menses. Further clinical trials are needed in this area.
- || sirolimus / Generic mfg.
Clinical, Journal: Addition of anti-estrogen treatment in patients with malignant PEComa progressing to mTOR inhibitors. (Pubmed Central) - Nov 25, 2021
Further clinical trials are needed in this area. In this small retrospective case series, the addition of anti-estrogen treatment in female patients with advanced PEComa progressing to mTOR inhibitors resulted in a remarkable clinical benefit in a setting where no other options are available.
- || progesterone / Generic mfg.
Clinical, Journal: Co-administration of GnRH agonists with vaginal progesterone compared to vaginal progesterone in luteal phase support of the frozen-thawed embryo transfer cycle: An RCT. (Pubmed Central) - Nov 24, 2021
However, in terms of clinical and ongoing pregnancy rates, the significant differences were seen between groups (p = 0.008 and p = 0.005, respectively). Co-administration of GnRH-a and vaginal progesterone in LPS may be superior to vaginal progesterone alone in women who underwent a frozen-selected embryo transfer cycle.
- Erleada (apalutamide) / J&J
LONG TIME RESPONSE IN NON-METASTATIC CRPC WITH APALUTAMIDE: FIRST CASE IN OUR REGION. () - Nov 20, 2021 - Abstract #PROSCABLADDR2021PROSCA_BLADDR_15;
CONCLUSIONS Apalutamide has been a breakthrough in the treatment of prostate cancer in advanced stages of the disease, significantly modifying the prognosis of patients at high risk of metastasis. The use of this treatment in clinical practice has shown surprising results that augur a modification of the indications of the drug for its use in different phases of the disease; as in the high-risk metastatic debut (TITAN Study).
- leuprorelin depot / Generic mfg., abiraterone acetate / Generic mfg.
MEDICAL SPENDING IN UROLOGY: AN IN-DEPTH VIEW OF ANDROGEN DEPRIVATION THERAPY AND ANTIANDROGEN COSTS () - Nov 19, 2021 - Abstract #SUO2021SUO_235;
More urologists are prescribing antiandrogens every year. The estimated cost per day for patients on antiandrogen therapy is substantially higher than ADT.
- || cetirizine oral / Generic mfg., leuprorelin depot / Generic mfg., triptorelin / Generic mfg.
Clinical, Journal: Vasculitis-like Palpable Purpuric Rush Induced by Decapeptyl in a Pediatric Patient Diagnosed Central Precocious Puberty: A Pediatric Case (Pubmed Central) - Nov 17, 2021
Her treatment for PCC was switched to Depot Leuprolide acetate and she continued her treatment for 2 years uneventfully. It should be kept in mind that in pediatric PCC patients who develop side effects like cutaneous vasculitis, the treatment may be continued by changing the preparation.
- ||||| Rekovelle (follitropin delta) / Ferring
Enrollment closed: Follitropin Delta in Long GnRH Agonist and GnRH Antagonist Protocols (BEYOND) (clinicaltrials.gov) - Nov 16, 2021
P3, N=437, Active, not recruiting, Sponsor: Ferring Pharmaceuticals
It should be kept in mind that in pediatric PCC patients who develop side effects like cutaneous vasculitis, the treatment may be continued by changing the preparation. Recruiting --> Active, not recruiting